PSA Screening for Aggressive Prostate Cancer Supported in Men With Lynch Syndrome

Men carrying MSH2 and MSH6 pathogenic variants, which are associated with Lynch syndrome, were found to have a higher incidence of prostate cancer compared with age-matched non-carrier individuals, supporting the value of annual, targeted prostate-specific antigen (PSA) screening from age 40 to identify men with clinically significant prostate cancer, according to the initial results of the IMPACT study (NCT00261456) that were published in The Lancet Oncology.¹

https://www.onclive.com/view/psa-screening-for-aggressive-prostate-cancer-supported-in-men-with-lynch-syndrome-associated-pathogenic-variants